€500m to push gene therapyGerman Christian democrats have started the election year underpinning their intention to pump money into life science research and into its translation into products. more ➔
Johnson & Johnson to buy Actelion for...Following a month-long take-over poker, J&Js and Actelions boards have agreed to support an all-cash tender offer from J&J in which shareholders are set to receive US$280.08 per share and … more ➔
HCC: resminostat boosts overall survivalGerman 4SC AGs epigenetic cancer drug resminostat is back. What seemed to be a flop after Phase II failure has being transformed into a success story of personalised medicine. By accurate data analysis … more ➔
GM mosquitoes to be released in India Oxford-based Intrexion-subsidiary Oxitec plans to release male GM mosquitoes that produce nonviable offspring in India, in order to limit the spread of dengue and chikungunya fevers transmitted by Aedes … more ➔
Biotech CEOs advise EU on breakthrough inn...Two biotech CEOs have been selected by the European Commission for the High Level Group. The EU think tank will provide strategic input to Horizon 2020 and a €2.5bn fund to support innovation by 2020 … more ➔
Affimed is seeking fundsWhile German Nasdaq company Affimed (AFMD) had an accumulated loss of over €100m, an annual development cost of about €38m for its Tandab pipeline, and an income of only about €8m from collaborations … more ➔
Octimet bags €11m for development of can... Belgian start-up company Octimet Oncology NV has secured €11.3m in a series A financing round. The funds will be used to develop two MET kinase blockers to treat solid tumours. more ➔
Joint-venture Fibrocor tackles fibrosis Drug screening expert Evotec AG and Ontario-based MaRS Innovation have launched the joint venture company Fibrocor Therapeutics LP to tackle fibrosis, an unmet medical need and multi-billion US dollars … more ➔
New technology speeds up mapping of DNA-pr...Scientists at EPFL have developed a technique that can be a game-changer for genetics by making the characterisation of DNA-binding proteins much faster, more accurate, and efficient. more ➔
Telix licenses Wilex girentuximab progra... German Wilex has licensed its clear cell renal cell carcinoma (ccRCC) antibody Redectane to Australian biopharma company Telix Pharmaceuticals. Redectane is a radiolabeled version of Wilex Phase III … more ➔
